| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inositol is a form of sugar your body needs to grow. myo-inositol is a sugar alcohol and a glucose isomer found in many food including grains and fruits. Inositol — Inositol is a naturally occurring six-carbon cyclitol (sugar alcohol-like carbohydrate), with myo-inositol being the predominant biologically active stereoisomer in humans and the form most commonly used as an oral supplement. It is formally classified as a nutrient/metabolic signaling molecule rather than an established anticancer drug; common abbreviations include MI, myo-Ins, and Ins. Myo-inositol is obtained from foods and is also synthesized endogenously from glucose-6-phosphate through ISYNA1-dependent metabolism. It is a precursor for phosphatidylinositol and phosphoinositide second-messenger systems. Myo-inositol should be distinguished from inositol hexaphosphate (IP6/phytic acid), which has substantially more preclinical anticancer literature and is listed separately in this database. Primary mechanisms (ranked):
Bioavailability / PK relevance: Myo-inositol is orally absorbed through sodium-dependent inositol transport systems, with human serum concentrations peaking approximately 1.5–3 hours after oral administration. A 100 mg/kg oral dose produced an estimated peak serum concentration of about 100 µM in a small human kinetic study. Bioavailability varies with formulation and can be reduced by competing D-chiro-inositol and some sugars/transporter substrates. Renal elimination is important. High-dose oncology studies have used approximately 18 g/day; gastrointestinal intolerance becomes dose-limiting at higher doses. In-vitro vs systemic exposure relevance: Exposure is concentration-driven. A recent DU-145 prostate-cancer study reported an approximate myo-inositol IC50 of 0.06 mg/mL after 72 hours, equivalent to about 330 µM; this is several-fold above the approximately 100 µM peak serum concentration observed after a 100 mg/kg oral human dose, although substantially higher oral doses have been used clinically. Some mechanistic experiments use still higher concentrations, so direct systemic translation of in-vitro cytotoxicity should be interpreted cautiously. Chemopreventive and signaling effects may occur below directly cytotoxic concentrations. Clinical evidence status: RCT-level chemoprevention evidence but no demonstrated anticancer efficacy. A randomized double-blind phase IIb trial used myo-inositol 9 g twice daily for six months in smokers with bronchial dysplasia. It did not significantly improve the primary dysplasia-response endpoint versus placebo, although BAL IL-6 decreased and responders showed reduced airway PI3K-activation signatures. Earlier phase I work established approximately 18 g/day as a tolerated dose and suggested lesion-regression activity. Myo-inositol is therefore best classified as an experimental chemopreventive/metabolic adjunct rather than an established cancer treatment. Inositol Cancer-Relevant Mechanisms
|
| Source: |
| Type: |
| Insulin Resistance - Reduced Cellular Responsiveness to Insulin Type: Metabolic phenotype / insulin-signaling dysfunction Function: Insulin resistance is a state in which target tissues respond inadequately to insulin, resulting in impaired glucose uptake and altered metabolic signaling. It is commonly associated with compensatory hyperinsulinemia, dysregulated PI3K/AKT signaling, inflammation, oxidative stress, mitochondrial dysfunction, and altered lipid metabolism. Cancer: ↑ Increased insulin resistance and associated hyperinsulinemia can promote a pro-tumorigenic metabolic environment through enhanced insulin/IGF signaling, inflammation, altered lipid metabolism, and increased growth-factor availability. The strength of this association varies by cancer type. Alzheimer's Disease: ↑ Increased peripheral and brain insulin resistance is associated with impaired neuronal glucose utilization, synaptic dysfunction, neuroinflammation, oxidative stress, abnormal tau phosphorylation, and altered amyloid processing. Improved insulin sensitivity is generally considered favorable. |
| 7638- | Ins, | d-Chiro-Inositol in Clinical Practice: A Perspective from the Experts Group on Inositol in Basic and Clinical Research (EGOI) |
| - | Review, | Nor, | NA |
| 7635- | Ins, | The Role of Inositols in Endocrine and Neuroendocrine Tumors |
| - | Review, | Thyroid, | NA |
| 7630- | Ins, | Modulation of both Insulin Resistance and Cancer Growth by Inositol |
| - | Review, | Var, | NA | - | Review, | Diabetic, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:101 Target#:1674 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid